AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$BWAY

Roth Yiftach sold 7,000 shares of BWAY

Roth Yiftach (Chief Scientist) sold 7,000 shares of Brainsway Ltd. (BWAY) across 4 trades over 2026-06-01 to 2026-06-02.

Original reporting
SEC EDGAR · Roth Yiftach
Published Jun 3, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BWAY
Neutral
high confidence
Mentioned
$BWAY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BWAYNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Primary relevance is limited to short‑term traders monitoring insider activity.

03

What to watch

Insider still holds over 1 million shares, indicating continued confidence.

Relevance 4/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions and are used by traders to gauge potential sentiment shifts.

Company-level read

Ticker impact

$BWAYNeutralHigh confidence
Context

Chief Scientist Roth Yiftach sold 7,000 shares in a Form 4 filing.

Expected impact

likely slight downward pressure as market prices in the insider sell.

Evidence & confidence

The sale represents a tiny fraction of the insider's holdings and no price was disclosed, limiting material impact.

Market effects

Sector

Minimal effect on the neurotechnology sector.

Regional

No discernible regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Brainsway Ltd.

    Neurotechnology firm listed on Nasdaq under BWAY.

  • Person
    Roth Yiftach

    Chief Scientist and insider of Brainsway.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BWAY insider trading history →

Related articles

SEP 8
$BWAYMedAI 8/10

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.

globenewswire.com2 min
AUG 13
$BWAYMedAI 8/10

Brainsway Q2 Earnings Call Highlights

BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.

yahoo.com4 min
AUG 12
$BWAYHighAI 9/10

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay Ltd. (NASDAQ, TASE: BWAY) reported Q2 2026 revenue up 35% to $17.1 million. Adjusted EBITDA more than doubled to $3.5 million (20% margin). Remaining performance obligations rose 30% to $80.4 million, and it shipped 125 Deep TMS systems (+42% YoY). The company raised FY2026 revenue guidance to $68-$70 million and Adjusted EBITDA to $13-$14 million.

finanznachrichten.de6 min
AUG 12
$BWAYHigh

Brainsway Ltd. (BWAY): Financial results for Q2 2026

Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding t

SEC EDGAR 6-K2 min